Ebola virus vaccine - Crucell/Vaccine Research Center
Alternative Names: VRC-EBOADV018-00-VPLatest Information Update: 25 Nov 2021
Price :
$50 *
At a glance
- Originator Vaccine Research Center
- Developer Crucell; Vaccine Research Center
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections
Most Recent Events
- 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
- 28 Feb 2008 Phase I development is ongoing
- 26 Sep 2006 Phase-I clinical trials in Ebola virus infections in USA (IM)